Comparative risk assessment using the margin of exposure (MOE) approach places cannabis at an MOE exceeding 10,000, compared with alcohol (MOE < 10 at the individual level) and heroinsupported
Cannabis had a margin of exposure (MOE) > 10,000, far exceeding all other drugs. Alcohol and nicotine fall in 'high risk' category with MOE < 10. srep08126
Animal LD50 values for THC are very high relative to any achievable human dose.supported
Cannabis had a margin of exposure (MOE) > 10,000, far exceeding all other drugs. Cannabis benchmarked as lowest acute toxicity risk of all drugs examined. srep08126
Claim in safety — inconclusiveinconclusiveworking →
At high doses or with high-potency preparations, disorientation, confusion, and acute psychotic episodes may occur in susceptible individuals.supported
Two cases of emergent psychosis after using concentrated THC extract known as cannabis wax, oil, or dabs. j.schres.2016.01.056
At high doses or with high-potency preparations, disorientation, confusion, and acute psychotic episodes may occur in susceptible individuals.supported
Dose-response relationship between cannabis and psychosis confirmed; high-potency cannabis varieties confer greatest risk. s2045796023000537
Tachycardia is the most consistent cardiovascular effect across all routes of administrationsupported
Tachycardia most common cardiovascular effect across all routes. 10826084.2024.2341317
Ventricular arrhythmias and myocardial infarction have been reported in the context of smoked cannabis, particularly with concurrent tobacco usesupported
Smoking associated with bronchitis, dyspnea, COPD, tachycardia, ventricular arrhythmias, and myocardial infarction. 10826084.2024.2341317
Claim in safety — inconclusiveinconclusiveworking →
Chronic cannabis smoking is strongly associated with chronic bronchitis, characterised by increased mucus production, cough, and airway inflammationsupported
Cannabis smoke strongly associated with symptoms of chronic bronchitis, histological signs of airway inflammation and remodelling. j.rmed.2023.107494
Chronic cannabis smoking is strongly associated with chronic bronchitis, characterised by increased mucus production, cough, and airway inflammationsupported
Smoking cannabis causes bronchitis and changes in lung function. add.15075
No convincing causal link between cannabis smoking and COPD has been established, though increased central airway resistance and lung hyperinflation are documentedsupported
No convincing evidence that this leads to COPD. Associated with increased central airway resistance, lung hyperinflation and higher vital capacity. add.15075
The association between cannabis smoking and lung cancer remains inconclusive; concurrent tobacco use amplifies respiratory risks synergisticallysupported
Link with lung cancer remains inconclusive. Concurrent tobacco use amplifies risks. br.2025.2058
Cannabis smoke has been associated with invasive pulmonary aspergillosis in immunocompromised individualssupported
Association with invasive pulmonary aspergillosis in immunocompromised subjects. j.rmed.2023.107494
Vaporisation avoids combustion byproducts; edibles are associated with minimal respiratory effects.supported
Cannabis edibles associated with minimal respiratory effects. 10826084.2024.2341317
Cannabinoid hyperemesis syndrome (CHS) is a condition of recurrent cyclic vomiting associated with chronic, heavy cannabis use, increasingly recognised in emergency departmentssupported
Cannabinoid hyperemesis syndrome (CHS), recurrent emesis from chronic cannabis use, increasingly observed in emergency departments. jamanetworkopen.2025.45310
CHS is classified under ROME-IV criteria as a specific variant of cyclic vomiting syndromesupported
CHS is classified in ROME-IV as specific variant of CVS. a-2704-5465
Full remission requires sustained cannabis abstinence; cannabis relapses cause progressively stronger and longer CHS episodes (sensitisation)supported
Full remission only through sustained abstinence. Cannabis relapses cause stronger and longer CHS clusters (sensitization). a-2704-5465
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Mycotoxins and mould: Aspergillus species are of particular concern for immunocompromised consumers.supported
Association with invasive pulmonary aspergillosis in immunocompromised subjects. j.rmed.2023.107494
Label accuracy: THC concentrations on commercial product labels may deviate by ±15% or more from actual content; analytical discrepancies between laboratories contribute to this uncertainty.supported
Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of actual content. journal.pone.0321832
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Epidemiological evidence consistently supports a dose-response relationship between cannabis use and psychosis risk; high-potency cannabis varieties confer the greatest risksupported
Dose-response relationship between cannabis and psychosis confirmed; high-potency cannabis varieties confer greatest risk. s2045796023000537
Epidemiological evidence consistently supports a dose-response relationship between cannabis use and psychosis risk; high-potency cannabis varieties confer the greatest risksupported
Dose-response relationship between cannabis and psychosis confirmed; multi-causal model with vulnerability interacting with precipitating agent. add.13826
Cannabis use functions as a component cause in multi-causal models of psychosis, where genetic vulnerability interacts with the precipitating substancesupported
Dose-response relationship between cannabis and psychosis confirmed; multi-causal model with vulnerability interacting with precipitating agent. add.13826
Psychosis associated with cannabis withdrawal has also been documented in a systematic reviewsupported
Abrupt cessation of heavy cannabis use can cause a withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite and restlessness. bjp.2024.175
Two case reports document emergent psychosis following use of high-potency wax concentrates in individuals without prior psychiatric history.supported
Two cases of emergent psychosis after using concentrated THC extract known as cannabis wax, oil, or dabs. j.schres.2016.01.056
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Cannabis dependence is the most common drug use disorder globally after opioid dependence, with an estimated 22.1 million cases in 2016supported
Cannabis dependence: 22.1 million cases globally in 2016 (age-standardised prevalence 289.7 cases per 100,000). Most common drug use disorder globally after opioid dependence. s2215-0366(18)30337-7
Cannabis withdrawal syndrome (CWS) is a DSM-5-recognised condition occurring in approximately 50% of regular and dependent users after abrupt cessation or significant dose reductionsupported
Cannabis withdrawal is a well-characterized phenomenon that occurs in approximately half of regular and dependent cannabis users after abrupt cessation. add.15743
Cannabis withdrawal syndrome (CWS) is a DSM-5-recognised condition occurring in approximately 50% of regular and dependent users after abrupt cessation or significant dose reductionsupported
Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. jamanetworkopen.2020.2370
Symptoms include irritability, anxiety, insomnia, reduced appetite, restlessness, and depressed moodsupported
withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite and restlessness. bjp.2024.175
Claim in safety — inconclusiveinconclusiveworking →
The principal pharmacokinetic concern is that THC and CBD inhibit CYP2C9 and CYP3A4 in a dose-dependent, reversible mannerpartially supported
Δ8-THC and 11-hydroxy-Δ8-THC significantly inhibited CYP2C9- and CYP3A4-mediated metabolism in a dose-dependent, reversible manner. j.dmd.2025.100122
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Opioids (morphine, oxycodone): Vaporised cannabis augments opioid analgesic effects through pharmacodynamic synergism without significantly altering plasma opioid levels, reducing pain by an average of 27% in a controlled studysupported
Vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. Pain significantly decreased by average 27% after addition of vaporized cannabis. clpt.2011.188
GABAergic anaesthetics (propofol, midazolam, isoflurane, sevoflurane): Clinical observations consistently document increased anaesthetic requirements in cannabis users; the molecular mechanism remains unclear.supported
Clinical studies and case reports have consistently shown increased requirements of GABAergic anesthetic drugs to achieve adequate levels of clinical anesthesia in cannabis users. ane.0000000000007313
Claim in safety — inconclusiveinconclusiveworking →
Tobacco/nicotine: Co-use synergistically amplifies respiratory risks, including lung cancer risksupported
Concurrent tobacco use amplifies risks. br.2025.2058
Prenatal cannabis exposure is significantly associated with lower birth weight, increased risk of preterm birth, small-for-gestational-age neonates, and NICU admissionpartially supported
Prenatal exposure to cannabis was significantly associated with lower birth weight in both human and rodent studies. can.2025.0027
Claim in safety — inconclusiveinconclusiveworking →
Prenatal cannabis exposure is significantly associated with lower birth weight, increased risk of preterm birth, small-for-gestational-age neonates, and NICU admissionsupported
Cannabis use during pregnancy is associated with risks including gestational hypertension, preterm birth, small for gestational age, low birth weight, NICU admission. jcp.24f15611
Claim in safety — inconclusiveinconclusiveworking →
Long-term follow-up studies document subtle but enduring effects on memory and externalising behaviours in offspringsupported
Prenatal cannabis exposure has subtle yet enduring effects on memory and achievement in children and adolescents; consistent effects on externalizing behaviors. j.pbb.2022.173358
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Personal or family history of psychotic disorders is a strong relative contraindication due to the dose-dependent association between cannabis use and psychosis precipitation.supported
Dose-response relationship between cannabis and psychosis confirmed; high-potency cannabis varieties confer greatest risk. s2045796023000537
Personal or family history of psychotic disorders is a strong relative contraindication due to the dose-dependent association between cannabis use and psychosis precipitation.supported
Dose-response relationship between cannabis and psychosis confirmed; multi-causal model with vulnerability interacting with precipitating agent. add.13826
Claim in safety — inconclusiveinconclusiveworking →
Significant cardiovascular disease is contraindicated due to tachycardia and potential for arrhythmias across all administration routes.supported
Tachycardia most common cardiovascular effect across all routes. Smoking associated with tachycardia, ventricular arrhythmias, and myocardial infarction. 10826084.2024.2341317
Claim in safety — inconclusiveinconclusiveworking →
The primary urinary analyte is 11-nor-9-carboxy-THC (THCCOOH), an inactive metabolitesupported
THC and 11-nor-9-carboxy-THC (THCCOOH) as primary analytes. hvaa113
The primary urinary analyte is 11-nor-9-carboxy-THC (THCCOOH), an inactive metabolitesupported
Workplace urine drug testing for inactive THC metabolite. s13181-016-0587-z
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Urine immunoassays demonstrate excellent specificity (100%) but variable sensitivity (63–74% for moderate users)supported
All matrices demonstrated excellent specificity (100%), largely adequate sensitivity (63-74%) except for oral fluid (12%). bkaf051
Oral fluid testing shows poor sensitivity (12% in one study)supported
largely adequate sensitivity (63-74%) except for oral fluid (12%). bkaf051
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A positive urine result confirms prior THC exposure; it does not document current impairment or recent use.supported
Positive result does not document impairment or recent use. s13181-016-0587-z